TSHA241220P500
- 0.00
- 0.000.00%
Taysha Gene Therapies Newsroom
JMP Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5
JMP Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5
Buy Rating for Taysha Gene Therapies Due to Safer Administration Method and Lower Viral Dose
Taysha Gene Therapies Analyst Ratings
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $8
Taysha Gene Therapies Price Target Maintained With a $6.00/Share by Needham
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $5 to $7.5
Taysha Gene Therapies: Promising Developments and Strong Financial Position Support Buy Rating
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $5 to $7
Positive Buy Rating for Taysha Gene Therapies Amidst Competitive Advantages Over Neurogene
Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $5 to $7
Taysha Gene Therapies Analyst Ratings
Baird Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $6
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
Baird Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
Optimism for Taysha Gene Therapies: Promising Preclinical Data and Upcoming Catalysts Drive Buy Rating